Charles River Labs: Is the Bumpy Ride Smoothing Out?
Update: 2025-10-02
Description
Charles River Labs stock jumps after Barclays upgrade signals easing drug discovery slowdown and stable pharma budgets. But with a history of volatility and underperformance, can Charles River adapt to the AI-driven future of biotech to truly reward long-term investors?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
